Background: Mesenchymal-to-epithelia transition (MET) exon 14 skipping (METex14) has been recognized as a potential driver alteration in lung cancers, and represents an emerging molecular target for lung cancer treatment. However, most studies about patient characterization and clinical outcomes of METex14-positive lung cancer were conducted in Caucasians, relevant data in Chinese patients were lacking. Here, we retrospectively characterized the clinical and molecular features of patients harboring MET mutations causing exon 14 skipping in a large cohort of Chinese lung cancers, and interrogated relevant clinical parameters associated with clinical outcomes of crizotinib treatment. Method: Genomic profiling data obtained from either plasma or tissue of 7,507 lung cancer patients with various histological types were screened to identify patients harboring METex14. Results: A total of 68 patients (0.91%), different from the frequency of Western population (3%), were identified to carry DNA alterations predicted to cause METex14 with a median age of 67.5, which is statistically significantly older than the whole cohort (p<0.001, t-test). In addition, METex14 has a female predominance (p¼0.036, Fisher's exact test). Mutation rates vary in different histological sub-groups: 0.80% in adenocarcinoma, 1.31% in squamous cell carcinoma, and 10.0% in sarcomatoid carcinoma. Collectively, a total of 68 variants (39 unique variants) predicted to cause METex14 were identified, including 7 point mutations and 10 indels affecting splice donor sites, 1 point mutations and 19 indels affecting splice acceptor sites, one point mutation at Y1003, one in-frame deletion within exon 14. Clinical outcomes of 18 METex14-positive patients treated with crizotinib were investigated. The median PFS and median OS were 7.3 and 8.5 months. Overall response rate in this sub-cohort was 22.2% (4/18) and disease control rate was 38.9% (7/18). Among them, METex14-positive patients harboring concurrent TP53 mutations had significant shorter OS than patients with wild type TP53 mutations (p¼0.0068). In addition, patients diagnosed as squamous cell lung cancers displayed favorable PFS and OS than adenocarcinomas (PFS, p¼0.39; OS, p¼0.26). Although statistical significance was not achieved due to limited patient number of squamous cell carcinomas, this result warranted further investigation into this observation. Conclusion: We comprehensively characterized METex14 in Chinese lung cancer patients with various histological types. Our data revealed that METex14 defined a unique clinical and molecular subset of lung cancers in Chinese patients. Our study also improved the knowledge of survival stratification in METex14-positive lung cancers and might be helpful for clinical therapeutic strategy design. Keywords: lung cancer, MET exon 14 skipping, Crizotinib However, their prognostic roles in early stage NSCLC were not well defined. In this study we sought to identify the pure prognostic role of TP53 mutation and TMN in patients with completely resected stage I NSCLC. Method: 244 patients of stage I (T1a-cN0) NSCLC who had been completely resected (1991-2014) with TP53 Mutation status and TMB data were collected from TCGA Database. TMB data was analyzed in 119 patients. Disease free survival (DFS) and overall survival (OS) were compared between TP53 mutation and wild-type mutation, higher TMN (>223.5) and lower TMN (<223.5). DFS and OS were estimated using Kaplan Meier methods and Cox regression models. Results: 244 patients were included in this study with 122 (50%) TP53 mutations. Multivariate analysis identified TP53 mutation tumors were associated significantly shorter OS (HR 2.31, 95%-CI 1.34 to 3.87; p¼0.002) and DFS (HR 1.80, 95%-CI 1.12 to 2.71;p¼0.005) compared to wild-type tumors. The TMN between TP53 mutation and wild-type mutation was significant (mean 332.1 vs 164.1; p¼0.001), TMN>223.5was associated with worse OS (HR 2.72, 95% CI 1.25-5.93, p¼0.012) and DFS (HR 1.79, 95% CI 1.01-3.15, p¼0.045). TMN>223.5 were identified as independent prognostic markers. Conclusion: TP53 and TMN＞223.5 are two independent prognostic factors in resected stage I lung adenocarcinoma. TP53 mutation might increase TMN which impact on the prognosis. 
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